Jin Medical International Azioni (NASDAQ: ZJYL)

Ultime notizie per Jin Medical International (NASDAQ:ZJYL) Azioni

Jin Medical International

Jin Medical International Ltd offers rehabilitation equipment. It is primarily engaged in the design, development, manufacturing, and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's products are sold to distributors in both China and in overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, nursing products, and conlo products.

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International Ltd

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Meta Platforms</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with META, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 31 uncommon options trades for Meta Platforms.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 38% bullish and 35%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $641,951, and 26 are calls, for a total amount of $1,896,313.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $400.0 to $820.0 for Meta Platforms over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Meta Platforms stands at 2470.58, with a total volume reaching 12,875.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Meta Platforms, situated within the strike price corridor from $400.0 to $820.0, throughout the last 30 days.</p>
<h3>Meta Platforms Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730817964_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$11.8</td>
<td>$11.6</td>
<td>$11.68</td>
<td>$540.00</td>
<td>$274.7K</td>
<td>5.6K</td>
<td style="text-align: right;">419</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$11.65</td>
<td>$11.45</td>
<td>$11.56</td>
<td>$610.00</td>
<td>$271.9K</td>
<td>2.3K</td>
<td style="text-align: right;">438</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$82.15</td>
<td>$81.6</td>
<td>$82.15</td>
<td>$500.00</td>
<td>$164.3K</td>
<td>12.0K</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$83.35</td>
<td>$82.15</td>
<td>$82.1</td>
<td>$500.00</td>
<td>$164.2K</td>
<td>12.0K</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$253.4</td>
<td>$252.2</td>
<td>$253.4</td>
<td>$820.00</td>
<td>$152.0K</td>
<td>11</td>
<td style="text-align: right;">6</td>
</tr>
</tbody>
</table>
</p>
<h3>About Meta Platforms</h3>
<p>Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.</p>
<p>In light of the recent options history for Meta Platforms, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Meta Platforms Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,457,256, with META's price down by -1.21%, positioned at $560.29.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 86 days.</li>
</ul>
<h3>Professional Analyst Ratings for Meta Platforms</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $665.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Raymond James continues to hold a Strong Buy rating for Meta Platforms, targeting a price of $650.<br />
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Meta Platforms, targeting a price of $650.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Meta Platforms, targeting a price of $650.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $670.<br />
&#x2A; An analyst from Citigroup persists with their Buy rating on Meta Platforms, maintaining a target price of $705. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Meta Platforms options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

Looking At Meta Platforms's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Booking Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BKNG, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Booking Holdings.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 77% bullish and 0%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $53,435, and 7 are calls, for a total amount of $528,728.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3600.0 and $5750.0 for Booking Holdings, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Booking Holdings's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Booking Holdings's whale activity within a strike price range from $3600.0 to $5750.0 in the last 30 days. </p>
<h3>Booking Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730817959_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1248.0</td>
<td>$1232.0</td>
<td>$1248.0</td>
<td>$3600.00</td>
<td>$124.8K</td>
<td style="text-align: right;">337</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1227.7</td>
<td>$1205.5</td>
<td>$1218.0</td>
<td>$3600.00</td>
<td>$121.8K</td>
<td style="text-align: right;">24</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$467.6</td>
<td>$442.6</td>
<td>$459.59</td>
<td>$4410.00</td>
<td>$91.9K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$818.9</td>
<td>$800.0</td>
<td>$818.9</td>
<td>$4150.00</td>
<td>$81.8K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$492.8</td>
<td>$488.6</td>
<td>$492.8</td>
<td>$4600.00</td>
<td>$49.2K</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
</p>
<h3>About Booking Holdings</h3>
<p>Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.</p>
<p>After a thorough review of the options trading surrounding Booking Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Booking Holdings Standing Right Now?</h3>
<ul>
<li>With a trading volume of 3,661, the price of BKNG is down by -0.14%, reaching $4770.0.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 107 days from now.</li>
</ul>
<h3>What The Experts Say On Booking Holdings</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $4852.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Booking Holdings, which currently sits at a price target of $4510.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Booking Holdings with a target price of $4600.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Booking Holdings with a target price of $5250.<br />
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Booking Holdings, which currently sits at a price target of $5000.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Booking Holdings with a target price of $4900. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Booking Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


BKNG

A Closer Look at Booking Holdings's Options Market Dynamics

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Alibaba Gr Hldgs</strong>.</p>
<p>Looking at options history for Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) we detected 13 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 46% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $339,810 and 6, calls, for a total amount of $238,260.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $115.0 for Alibaba Gr Hldgs during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Alibaba Gr Hldgs's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Alibaba Gr Hldgs's substantial trades, within a strike price spectrum from $90.0 to $115.0 over the preceding 30 days.</p>
<h3>Alibaba Gr Hldgs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730817954_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$14.9</td>
<td>$14.65</td>
<td>$14.65</td>
<td>$110.00</td>
<td>$73.2K</td>
<td>6.0K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$11.45</td>
<td>$11.35</td>
<td>$11.35</td>
<td>$105.00</td>
<td>$56.7K</td>
<td>2.5K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$14.0</td>
<td>$13.9</td>
<td>$14.0</td>
<td>$110.00</td>
<td>$56.0K</td>
<td>1.6K</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.0</td>
<td>$13.35</td>
<td>$14.0</td>
<td>$90.00</td>
<td>$56.0K</td>
<td>10.1K</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.0</td>
<td>$12.7</td>
<td>$13.0</td>
<td>$110.00</td>
<td>$52.0K</td>
<td>4.9K</td>
<td style="text-align: right;">40</td>
</tr>
</tbody>
</table>
</p>
<h3>About Alibaba Gr Hldgs</h3>
<p>Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.</p>
<p>Having examined the options trading patterns of Alibaba Gr Hldgs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Alibaba Gr Hldgs Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 6,120,305, the BABA's price is up by 1.12%, now at $98.67. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 10 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Alibaba Gr Hldgs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


BABA

Check Out What Whales Are Doing With BABA

<p>Deutsche Bank  analyst Melissa Weathers   maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and lowers the price target from $56 to $50.</p>


News

Price Target

Analyst Ratings

LSCC

Deutsche Bank Maintains Buy on Lattice Semiconductor, Lowers Price Target to $50

Macro Economic Events

Econ #s

Economics

S&P Global Composite PMI For Oct. 54.1 Vs 54.3 Expected; 54.0 Prior

USA S&P Global Services PMI For October 55.0 Vs 55.3 Est.; 55.2 Prior

<p>Deutsche Bank  analyst Bryan Kraft   maintains Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) with a Buy and raises the price target from $42 to $47.</p>


FOXA

Deutsche Bank Maintains Buy on Fox, Raises Price Target to $47

<p>Deutsche Bank  analyst Melissa Weathers   maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Buy and lowers the price target from $145 to $115.</p>


ENTG

Deutsche Bank Maintains Buy on Entegris, Lowers Price Target to $115

<p><strong>Archer-Daniels-Midland Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower on Tuesday.</a></p>
<p>Yesterday, the company reported third-quarter preliminary adjusted earnings per share of $1.09, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41733821/adm-reports-preliminary-third-quarter-2024-results" rel="noreferrer noopener">compared with street view of $1.25.</a></p>
<p>The company will restate previously filed fiscal year 2023 Form 10-K and subsequent Forms 10-Q. The company said it has decided to postpone the webcast originally scheduled for November 5 at 9 a.m. Central Time.</p>
<p>The restated filings will include corrections for newly identified errors related to intersegment sales, will reflect the previously-corrected errors, and will provide disclosures applicable to restated segment information.</p>
<p>&#8220;Our third quarter operating results were mixed in a challenging quarter for the business,&#8221; said Chair of the Board and CEO Juan Luciano.</p>
<p>Archer-Daniels-Midland said net earnings are expected to be $18 million, with adjusted net earnings forecasted at $530 million. The company also anticipates a $461 million non-cash charge against GAAP earnings for the third quarter related to its Wilmar equity investment.</p>
<p>&#8220;We are taking the necessary actions to improve performance and drive continued value creation,&#8221; Luciano added.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41736062/boeing-workers-end-seven-week-strike-by-accepting-new-contract-with-major-pay-increases" rel="noreferrer noopener">Boeing Workers End Seven-Week Strike By Accepting New Contract With Major Pay Increases</a></strong></p>
<p>Ag Services and Oilseeds (AS&amp;O) segment operating profit was $480 million during the third quarter of 2024, down 43% compared to the prior-year quarter. Carbohydrate Solutions segment operating profit was $452 million for the third quarter of 2024, down 3% compared to the prior year period. Nutrition segment operating profit was $105 million for the third quarter of 2024, down 19% compared to the prior year period.</p>
<p>&#8220;While Carbohydrate Solutions achieved strong results, our Ag Services and Oilseeds and Nutrition businesses delivered results below expectations, impacted by softer than expected market conditions and the pace of our planned improvement efforts,&#8221; added Luciano.</p>
<p><strong>Outlook</strong>: The company has lowered its 2024 adjusted EPS guidance to a range of $4.50 &#8211; $5.00, down from the previous range of $5.25 &#8211; $6.25, and <a href="https://www.benzinga.com/calendars/guidance">below the $5.23 analyst estimate.</a></p>
<p>The company&#8217;s revised outlook reflects trends in ADM&#8217;s performance to date, legislative and regulatory policy uncertainties, and ongoing headwinds from slower market demand and internal operational challenges.</p>
<p><strong>Price Action: </strong>ADM shares are trading lower by 9.3% to $50.16 at last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/24/11/41734875/palantirs-ai-gamble-pays-off-as-customer-revenue-from-single-customer-jumps-12x-in-under-8-month" target="_blank" rel="noreferrer noopener">Palantir&#8217;s AI Gamble Pays Off As Customer Revenue From Single Customer Jumps 12x In Under 8 Months — Alex Karp Quips: &#8216;We Should Just Go Home&#8217;</a></strong></li>
</ul>


Earnings

Equities

Guidance

Movers

General

Archer-Daniels-Midland Stock Dips After Q3 Preliminary Results: Earnings Miss, Guidance Cut Amid Restatements

<p>Lake Street  analyst Eric Martinuzzi   upgrades Brightcove (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOV#NASDAQ">BCOV</a>) from Hold to Buy and raises the price target from $2.75 to $3.5.</p>


Upgrades

BCOV

Lake Street Upgrades Brightcove to Buy, Raises Price Target to $3.5

<p>Deutsche Bank  analyst Ross Seymore   maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy and raises the price target from $60 to $100.</p>


ALAB

Deutsche Bank Maintains Buy on Astera Labs, Raises Price Target to $100

<p>Deutsche Bank  analyst Brian Bedell   maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Buy and raises the price target from $65 to $67.</p>


Deutsche Bank Maintains Buy on TPG, Raises Price Target to $67

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   reiterates Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and maintains $221 price target.</p>


Reiteration

KRYS

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

WIIM

TDUP

ThredUp shares are trading higher after the company reported better-than-expected Q3 EPS and sales and slightly raised its FY2024 sales guidance.

<p>Deutsche Bank  analyst Brian Bedell   maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Hold and lowers the price target from $20 to $19.</p>


Deutsche Bank Maintains Hold on Franklin Resources, Lowers Price Target to $19

<p>Deutsche Bank  analyst Brian Bedell   maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Buy and raises the price target from $51 to $56.</p>


Deutsche Bank Maintains Buy on Brookfield Asset Mgmt, Raises Price Target to $56

EGHT

8x8 shares are trading higher after the company reported better-than-expected Q2 EPS and sales.

<p>Deutsche Bank  analyst Brian Bedell   maintains Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) with a Buy and lowers the price target from $219 to $204.</p>


Deutsche Bank Maintains Buy on Affiliated Managers Group, Lowers Price Target to $204

<p>HC Wainwright &amp; Co.  analyst Douglas Tsao   reiterates Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Buy and maintains $70 price target.</p>


IRON

HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target

<p><strong>Trio Petroleum Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>) shares are trading lower by 19% to 10 cents Tuesday morning after the company announced a <a href="https://www.benzinga.com/pressreleases/24/11/g41727117/trio-petroleum-corp-announces-reverse-stock-split">1-for-20 reverse stock split</a>, approved by its board and shareholders, to take effect on November 14. </p>
<p><strong>What To Know:</strong> This split will consolidate every 20 shares of common stock into 1 share, affecting all outstanding shares equally. Stockholders' ownership percentages will remain the same, though fractional shares will be rounded up. </p>
<p>Adjustments will also be made to Trio's equity awards. The stock will begin trading on a post-split basis on November 15, under the same symbol (TPET) with a new CUSIP number.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a></strong></p>
<p>According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TPET has a 52-week high of $0.72 and a 52-week low of $0.08.</p>


TPET

Why Trio Petroleum (TPET) Stock Is Trading Lower

PHIO and MGRM among healthcare movers

VERI, CHEK and MESO are among pre market gainers

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has regained compliance with Nasdaq's public holders r...

Jin Medical Regains Nasdaq Compliance, Aims for Timely Filing

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical Technologies Ltd. faces scrutiny as its former auditor, DNTW Toronto LLP,...

Jin Medical Auditor Resigns Amid Dispute

WIRE, CUTR and USEG are among premarket  gainers

Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has successfully regained compliance with Nasdaq's fil...

Jin Medical Regains Nasdaq Compliance

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>June may not be the first month you consider when you plan to invest, but this isn&rsquo;t a month that should be overlooked. June is an ideal time to look for A-rated <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> to diversify your portfolio and lead to some potentially lucrative returns.</p>



<p>Penny stocks are shares of companies with stock valued under $5. It&rsquo;s appealing to investors since they can acquire a significant stake in a company with a small investment.</p>



<p>However, not all penny stocks are created equal, and the risks associated with them can be substantial. This is where A-rated penny stocks come into play.</p>



<p>A-rated penny stocks get their rankings from the Portfolio Grader, which assigns stocks a letter grade based on earnings performance, growth, analyst sentiment and buying momentum. By keeping your eye on A-rated penny stocks, you&rsquo;re assured of getting the best of these low-priced stocks and setting yourself up for a better overall return.</p>



<p>And with June being a popular month for companies to file earnings reports, investors are armed with new information about these companies&rsquo; performance and outlook.</p>



<p>There are seven A-rated penny stocks on today&rsquo;s list, and any of them would be a solid addition to a portfolio while mitigating the risks that are commonly associated with smaller companies.</p>



<h2>Lexaria Bioscience (LEXX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div><p>Biotech companies can be challenging investments. Bringing a drug to market is no small feat, as it requires millions of dollars in research and development and multiple successful clinical trials before you can even consider seeking regulatory approval and achieve commercialization.</p>



<p>But <strong>Lexaria Bioscience</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/lexx-stock-quote/"><strong>LEXX</strong></a>) is an exception to the rule. The company is the creator of DehydraTECH, which is a drug delivery technology that improves the way active drugs enter the bloodstream.</p>



<p>DehydraTECH increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled tablets, capsules and oral suspensions because it can mask the taste of medications.</p>



<p>Biotechs can incorporate the DehydraTECH platform into any of their oral medications to make them more effective and tolerable for patients.</p>



<p>Any drug delivery system that makes medications more effective and more tolerable to patients is going to be popular in the biotech field.</p>



<p>The DehydraTECH platform increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled products because it can mask the taste of medications.</p>



<p>At the end of the <a href="https://ir.lexariabioscience.com/financial-information/financial-results">second quarter</a>, Lexaria was in a strong cash position, with $4.7 million on hand. Revenue in the quarter was only $145,000, but that is better than the $20,000 the company received in the second fiscal quarter of 2023. The company reported a loss of $668,000, but its losses are significantly dropping as the company edges toward profitability.</p>



<p>LEXX stock is up 130% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>JanOne (JAN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div><p><strong>JanOne</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/jan-stock-quote/"><strong>JAN</strong></a>) is yet another bioscience company. It is developing nonaddictive treatments for conditions that cause severe pain. Its work is dedicated to helping people manage their pain without getting hooked on a treatment and developing a dependency for a drug, such as opioids.</p>



<p>Its most promising drug in the pipeline is a treatment for peripheral artery disease. The drug candidate has successfully completed Phase 2A trials and is awaiting Phase 2B testing to treat the disease and the pain associated with peripheral artery disease.</p>



<p>In addition, JanOne has a wholly owned subsidiary called <a href="https://ir.janone.com/news-events/press-releases/detail/71/janones-subsidiary-alt5-reports-91-year-over-year">ALT5 Sigma</a>, which is a fintech company that provides next-generation blockchain powered technologies. The company processed $289 million in cryptocurrency transactions in April and May combined, which was a 91% increase from a year ago.</p>



<p>JanOne offers an interesting way to invest in biotech and also play the cryptocurrency space. The stock is up 333% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Ocugen (OCGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/ocgn1600-300x169.png" alt="Person holding smartphone with logo of US biopharmaceutical company Ocugen Inc. (OCGN) on screen in front of website. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p>As a small biotech company headquartered in Pennsylvania, <strong>Ocugen</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocgn-stock-quote/"><strong>OCGN</strong></a>) is making its mark by developing and commercializing gene and cell therapies.</p>



<p>The company is also getting a nice boost on June 28 when it joins the Russell 3000 index, which measures the performance of the largest 3,000 U.S. companies. Its inclusion means that Ocugen stock will be included in exchange traded funds and products that track the Russell 3000.</p>



<p>Ocugen is working on a breakthrough modifier gene therapy product that might treat multiple retinal diseases with a single product. It also has several products in various phases of testing to treat eye diseases.</p>



<p>Ocugen showed $13.2 million in operating expenses for the first quarter and had $26.4 million of cash on hand. It posted a loss of 5 cents per share versus a loss of 8 cents per share a year ago.</p>



<p>Losses for small biotech companies are to be expected as it takes time and money to bring new therapies to market. But OCGN stock is one of the better penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> you can buy, as the stock is up 124% so far this year. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Kuke Music (KUKE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/02/music_1600-300x169.jpg" alt="A photo of someone writing out music on staff paper with guitars in the background."><div>Source: Kemedo/ShutterStock.com</div></div><p><strong>Kuke Music</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/kuke-stock-quote/"><strong>KUKE</strong></a>) is a digital music company in China. The company is a leading provider of classical music licensing, subscriptions and smart education services in China.</p>



<p>The company leverages its diverse content offerings and experience in music education to provide smart music education products, including Kuke smart pianos and Kuke smart teaching systems.</p>



<p>The company is also the organizer of the Beijing Music Festival and is working to get into the AI music field through a <a href="https://finance.yahoo.com/news/kuke-jidou-join-forces-ai-122000084.html">partnership</a> with <strong>Shanghai Jidou Science and Technology</strong>, which will see Kuke lauch an AI music application through a digital automotive software platform that Jidou develops for more than a dozen automotive companies.</p>



<p><a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&amp;ref=318325464&amp;type=HTML&amp;cdn=2794ad5ad1fb979a4aae2110f8badbd2&amp;formType=20-F&amp;dateFiled=2024-05-15&amp;cik=0001809158&amp;symbol=0001809158&amp;companyName=">Kuke and its subsidiaries</a> reported revenue in 2023 of 106.9 million Chinese yuan ($14.7 million) and a loss of 65.8 million Chinese yuan. But the AI music partnership provides a path for Kuke to turn those losses into profits.</p>



<p>KUKE stock is up 101% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Jin Medical (ZJYL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-single-300x169.jpg" alt="A close up photo of a penny. Penny Stocks to Buy"><div>Source: Shutterstock</div></div><p><strong>Jin Medical</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/zjyl-stock-quote/"><strong>ZJYL</strong></a>) is another Chinese penny stock. The company makes and sells wheelchairs and other products for the elderly and those with disabilities.</p>



<p>The company operates two manufacturing plants with approximately 228,257 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. And it has relationships with more than 40 distributors in China and distributors in 20 other regions.</p>



<p>The majority of the company&rsquo;s wheelchair products, which includes 30 models, are sold in China and Japan.</p>



<p>As a Chinese company, Jin doesn&rsquo;t report its financials as often as those based in the U.S. But its <a href="https://ir.zhjmedical.com/se%D1%81filings">most current financial report</a> for the 2023 fiscal year (ending Sept. 30, 2023), included revenue of $19.8 million, up 3% from a year ago. </p>



<p>Profits of $6.7 million were up 9.5% from the 2022 fiscal year, and total net income of $2.87 million was a 6.3% improvement from the previous year.</p>



<p>ZJYL stock, which had its initial public offering only a year ago, is having a rough 2024. The company performed a <a href="https://investorplace.com/2024/02/why-is-jin-medical-international-zjyl-stock-moving-today/">20-for-1 stock split,</a> which brought the stock price down from $217 to roughly $13.50. However, the stock has been slipping ever since, and is down in penny stock territory.</p>



<p>However, I&rsquo;m expecting a rebound based on the company&rsquo;s financials, and the stock currently maintains its &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Caravelle International (CACO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/tech-stocks-1600-300x169.png" alt="A hexagonal grid with different tech-related icons; Tech stocks illustration. Best Tech stocks. tech stocks trading at bargain prices"><div>Source: whiteMocca / Shutterstock</div></div><p><strong>Caravelle International</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/caco-stock-quote/"><strong>CACO</strong></a>) is a global ocean technology company with headquarters in Singapore. The company has routes to 50 companies and serves more than 100 ports.</p>



<p>Caravelle&rsquo;s innovation lies in its work with shipping and lumber industries. The company invented a patent pending process called CO-Tech, which uses the heat from its ships&rsquo; exhaust to dry wood during transportation.</p>



<p>Caravelle says the process is an improvement from the lumber industry&rsquo;s practice of building and maintaining wood drying facilities and the energy required to heat the wood in those facilities.</p>



<p>Contrast this to the traditional wood desiccation process where lumber companies must build and maintain expensive wood drying facilities, spend money on energy to heat the wood, and emit massive amounts CO2.</p>



<p>The company already has a <a href="http://www.caravelleglobal.com/news-detail.html?newId=1783843089586188289">memorandum of understanding</a> with the government of Gabon to provide dried timber. If it can expand the business model to other governments, Caravelle may have a groundbreaking business on its hands.</p>



<p>CACO stock is up 63% this year, but is still priced at less than $1 per share. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Eco Wave Power (WAVE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1932365063-300x169.png" alt="Environmental protection, renewable, sustainable energy sources. Plant growing in the bulb concept. renewable energy stocks to buy"><div>Source: Proxima Studio / Shutterstock.com</div></div><p><strong>Eco Wave Power</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/wave-stock-quote/"><strong>WAVE</strong></a></span>) is a clean energy company that develops electricity from the power of ocean waves. </p>



<p>If you&rsquo;ve ever been caught in a rough surf you know that even those waves can pack a punch, so imagine the power that an ocean wave can provide should we be able to harness that power and turn it into a clean source of electricity.</p>



<p>The company&rsquo;s floaters can be attached to human-made structures to simplify installation and maintenance. The floaters draw energy from incoming waves by converting the rising and falling motion into a clean energy generation process.</p>



<p>The company currently works with customers in Israel, Portugal, Los Angeles and Gibraltar, a British territory. </p>



<p>While there was no revenue in the first quarter and the company sustained an operating loss of $659,000, management has high hopes that the company&rsquo;s clean energy solution will be a powerful argument for coastal cities.</p>



<p>WAVE stock is up 79% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More:</strong>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/market360/2024/06/7-a-rated-penny-stocks-to-beat-june-gloom/">7 A-Rated Penny Stocks to Beat June Gloom</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 A-Rated Penny Stocks to Beat June Gloom

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has shown a robust financial performance in their late...

Jin Medical's Asset Growth Amidst Revenue Dip

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd., a leader in Assistive Technologies manufacturing, has...

JinMed Expands with New High-Tech Facility

ABVC

ALLR

ANTE

APYX

ARGX

BPTH

BROG

CACO

CRDL

CZOO

DERM

DNUT

FLGC

HUBC

HUSA

INCR

INDO

KUKE

LEXX

LGVN

LOBO

LUXH

LXRX

MGRM

NKGN

NSYS

NUVB

OCGN

PHIO

PRAX

PROK

PRZO

PYXS

RENT

RVPH

STRO

TARA

TRML

WAVE

WINT

XFOR

ZJYL

Press Releases

JIN MEDICAL INTERNATIONAL LTD. Secures RMB66 Million in Orders for Innovative Micro-Hyperbaric Oxygen Chamber Equipment

JIN MEDICAL INTERNATIONAL LTD. Empowers "Lao Le Hui" Assisted Bathing Project with Portable Nano-thermal Therapy Bath

JIN MEDICAL INTERNATIONAL LTD. Enters into Memorandum of Understanding to Acquire Medical Equipment Sharing Platform

Opinion

Thinking about buying stock in Applied UV, Alphabet Inc, Alcoa, British American Tobacco, or Jin Medical International?

Comments

Jin Medical International

Notizie

Ultime notizie per Jin Medical International (NASDAQ:ZJYL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO